OR WAIT null SECS
January 22, 2025
Article
Self-reported primary prevention aspirin use decreased among adults with both low and high ASCVD risk after the release of evidence-based guidelines.
January 21, 2025
Approximately 2.0% of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis.
Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.
January 20, 2025
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025.
January 17, 2025
Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial's primary endpoint.
January 15, 2025
A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.
January 11, 2025
Aspirin avoidance remained safe and did not increase thrombosis risk after LVAD implantation in patients with a history of atherosclerotic vascular conditions.
January 10, 2025
Submission of the supplemental NDA was based on positive findings from the FINEARTS-HF trial investigating finerenone for heart failure with an LVEF ≥40%.
January 08, 2025
An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.
January 07, 2025
Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.